Addex Therapeutics Ltd. income statement

In fiscal 2025, Addex Therapeutics Ltd. reported revenue of $36,178, down 92.1% on the year before, operating income of −$3.4m (a -9390.8% margin) and net income of −$8.1m, or −$8.69 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Addex Therapeutics Ltd.: income statement, annual
Fiscal year	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	6	3	4	3	1	2	0	0
Research and development	5	13	11	14	9	1	1	1
Operating income	−1	−15	−13	−17	−11	−2	−3	−3
Interest expense	0	0	0	0	0	0	0	0
Income before tax	−2	−15	−14	−17	−11	−3	−6	−8
Income tax	0	0	0	0	0	0	0	0
Net income	−2	−15	−14	−17	−22	−12	8	−8
Diluted EPS	—	−$67.63	−$61.41	−$59.07	−$57.85	−$18.71	$9.54	−$8.69
Diluted shares (average)	—	—	—	—	—	—	—	—
EBITDA	−1	−14	−13	−17	−11	−2	−3	−3

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ADXN vs LYEL ADXN vs AIM ADXN vs IBIO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Addex Therapeutics Ltd.'s SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Addex Therapeutics Ltd.